Sirtuins - Modulation of their activity as a novel therapeutic target;Sirtuiny, modulacja aktywności jako nowy cel terapeutyczny

Polski Merkuriusz Lekarski

Volumn 28, Issue 165, 2010, Pages 231-235

  Kucińska, MaŁgorzata ^a   Piotrowska, Hanna ^a   Murías, Marek ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Activation; Aging related diseases; Inhibition; Sirtuins

Indexed keywords

NEUROPROTECTIVE AGENT; SIRTUIN; SIRTUIN 1;

AGED; AGING; ANGIOGENESIS; ANIMAL; APOPTOSIS; ARTICLE; DRUG EFFECT; HUMAN; LONGEVITY; METABOLISM; NEOPLASM; PARKINSON DISEASE; PHYSIOLOGY; DRUG EFFECTS; NEOPLASMS;

AGED; AGING; ANIMALS; APOPTOSIS; HUMANS; LONGEVITY; NEOPLASMS; NEOVASCULARIZATION, PHYSIOLOGIC; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; SIRTUIN 1; SIRTUINS;

EID: 77951249175     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Aggarwal B.B., Bhardwaj A., Aggarwal RS.i wsp.: Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res., 2004. 24 (5A), 2783-2840.
2. Alcain F.J., Villalba J.M.: Sirtuin activators. Expert. Opin. Ther. Pat, 2009, 19 (4), 403-414.
3. Alcain F.J., Villalba J.M.: Sirtuin inhibitors. Expert. Opin. Ther. Pat, 2009, 19 (3), 283-294.
4. Anekonda T.S., Reddy P.H.: Neuronal protection by sirtuins in Alzheimer's disease. J. Neurochem., 2006, 96 (2), 305-313.
5. Avalos J.L., Boeke J.D., Wolberger C.: Structural basis for the mechanism and regulation of Sir2 enzymes. Mol. Cell, 2004, 12, 13 (5), 639-648.
6. Borra M.T., Smith B.C., Denu J.M.: Mechanism of human SIRT1 activation by resveratrol. J. Biol. Chem., 2005, 29, 280 (17), 17187-17195.
7. Brooks CL., Gu W.: p53 Activation: a case against Sir. Cancer Cell, 2008, 13 (5), 377-378.
8. Elliott P. J., Jirousek M.: Sirtuins: novel targets for metabolic disease. Curr. Opin. Investig. Drugs, 2008, 9 (4), 371-378.
9. Feige J.N., tagouge M., Canto C i wsp.: Specific SIRTI activation mimics low energy levels and protects against diet-induced metabolic disorders by enhancing fat oxidation. Cell Metab., 2008, 8 (5), 347-358.
10. Firestein R., Blander G., Michan S. i wsp.: The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. PLoS One, 2008, 3 (4), e2020.
11. Garske A.L, Smith B.C., Denu J.M.: Linking SIRT2 to Paridnson's disease. ACS Chem. Biol., 2007, 17, 2 (8), 529-532.
12. Gescher A.J., Steward W.P.: Relationship between mechanisms, bioavailibility, and preclinical chemopreventive efficacy of resveratrol: a conundrum. Cancer Epidemiol. Biomarkers Prev., 2003, 12 (10), 953-957.
13. Guarente L., Picard F.: Calorie restriction - the SIR2 connection. Cell, 2005, 25, 120 (4), 473-4.82.
14. Heltweg B., Gatbonton T., Schuler AD. i wsp.: Antitumor activity of a smallmolecule inhibitor of human silent information regulator 2 enzymes. Cancer Res., 2006, 15, 66 (8), 4368-4377.
15. Kim D., Nguyen M.D., Dobbin M.M. i wsp.: SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis. EMBO J., 2007, 11, 26 (13), 3169-3179.
16. Kwon H.S., Brent M.M., Getachew R. i wsp.: Human immunodeficiency vims type 1 Tat protein inhibits the SIRT1 deacetylase and induces T cell hyper activation. Cell Host Microbe, 2008. 13, 3 (3), 158-167.
17. Lagouge M., Argmann C., Gerhart-Hines Z. i wsp.: Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell, 2006, 15, 127 (6), 1109-1122.
18. Lara E., Mai A., Calvanese V. i wsp.: Salermide, a Sirtuin inhibitor with a strong cancer-specific pmapoptotic effect. Oncogene, 2009, 12, 28 (6), 781-791.
19. Meziane H., Dodart J.C, Mathis C i wsp.: Memory-enhancing effects of secreted forms of the beta-amyloid precursor protein in normal and amnestic mice. Proc. Natl. Acad. Sci. USA, 1998,13, 95 (21), 12683-12688.
20. Pagans S., Pedal A., North B.J. i wsp.: SIRT1 regulates HIV transcription via Tat deacetylation. PLoS Biol., 2005, 3 (2), e41.
21. Potente M., Dimmeler S.: Emerging roles of SIRTI in vascular endothelial homeostasis. Cell Cycle, 2008, 15, 7 (14), 2117-2122.
22. Qin W., Yang T., Ho L. i wsp.: Neuronal SIRT1 activation as a novel mechanism underlying the prevention of Alzheimer disease amyloid neuropathology by calorie restriction. J. Biol. Chem., 2006, 4, 281 (31), 21745-21754.
23. Sauve A.A., Wolberger C, Schramm V.L. i wsp.: The biochemistry of sirtuins. Annu. Rev. Biochem., 2006, 75, 435-465.
24. Schwer B., Verdin E.: Conserved metabolic regulatory functions of sirtuins. Cell Metab., 2008, 7 (2), 104-112.
25. Smith J.J., Kenney .D. Gagne D.J. i wsp.: Small molecule activators of SIRT1 replicate signaling pathways triggered by calorie restriction in vivo. BMC Syst. Biol., 2009, 3, 31.
26. Solomon J.M., Pasupuleti R., Xu L. i wsp.: Inhibition of SIRT1 catalytic activity increases p53 acetylation but does not alter cell survival following DNA damage. Mol. Cell Biol., 2006. 26 (1), 28-38.
27. Taylor D.M., Maxwell M.M., Luthi-Carter R. I wsp.: Biological and potential therapeutic roles of sirtuin deacetylases. Cell MoI. Life Sd., 2008, 65 (24), 4000-4018.
28. Vakhrusheva O., Smolka C., Gajawada P. i wsp.: Sirt7 increases stress resistance of cardiomyocytes and prevents apoptosis and inflammatory cardiomyopathy in mice. Circ. Res., 2008, 28, 102 (6), 703-710.
29. Yamamoto H., Schoonjans K., Auwerx J.: Sirtuin functions in health and disease. Mol. Endocrinol., 2007, 21 (8), 1745-1755.